(Q33428782)

26 July 2017

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay (English)

1 reference

26 July 2017

7

Robert Zeillinger

0 references

author name string

Veronika Auner

1

1 reference

26 July 2017

Gernot Kriegshäuser

2

1 reference

26 July 2017

Dan Tong

3

1 reference

26 July 2017

Reinhard Horvat

4

1 reference

26 July 2017

Alexander Reinthaller

5

1 reference

26 July 2017

Alexander Mustea

6

1 reference

26 July 2017

language of work or name

English

0 references

publication date

9 April 2009

1 reference

26 July 2017

1 reference

26 July 2017

9

1 reference

26 July 2017

111

1 reference

Creative Commons Attribution 2.0 Generic

26 July 2017

start time

9 April 2009

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2407-9-111

0 references

cites work

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

K-RAS mutations in ovarian and extraovarian lesions of serous tumors of borderline malignancy.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Diagnostic biochip array for fast and sensitive detection of K-ras mutations in stool

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Genetic alterations in ovarian borderline tumours and ovarian carcinomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

ras oncogenes in human cancer: a review

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 June 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-111

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-111

Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-111

A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-9-111

Epidermal growth factor receptor (EGFR) mutation does not correlate with platinum resistance in ovarian carcinoma. Results of a prospective pilot study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2671522

Genetic alterations in endometrial hyperplasia and cancer

31 October 2018

1 reference

12 December 2020

Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors

1 reference

12 December 2020

p53 and Ki-ras gene mutations in epithelial ovarian neoplasms

1 reference

12 December 2020

K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases

1 reference

12 December 2020

Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors

1 reference

12 December 2020

Biochip for K-ras Mutation Screening in Ovarian Cancer

1 reference

12 December 2020

KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants

1 reference

12 December 2020

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

1 reference

12 December 2020

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-9-111

1 reference

Dimensions Publication ID

26 July 2017

1002772136

0 references

Fatcat ID

release_k3xm76ewovcxrdsbd2h4tj6vka

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/k3xm76ewovcxrdsbd2h4tj6vka

24 November 2022

mapped directly with Wikidata item

PMCID

2671522

1 reference

26 July 2017

1 reference